Buzdar A U, Legha S S, Hortobagyi G N, Powell K C, Blumenschein G R, Bodey G P
Am J Clin Oncol. 1982 Aug;5(4):383-7. doi: 10.1097/00000421-198208000-00006.
A combination of AMSA and peptichemio was evaluated in patients with advanced breast cancer refractory to conventional chemotherapy. Of 33 evaluable patients, five patients (15%) achieved partial remission, two patients (6%) had less-than-partial remission, nine patients (27%) had stable disease, and seventeen patients (52%) had progressive disease. The median duration of response was 6 months (range: 3-8 months). The median duration of stable disease was 5 months (range: 2-7 months). Myelosuppression was the dose-limiting toxicity. This combination of AMSA and peptichemio did not result in an improved response rate or duration of remission compared to the previous experience with single-agent therapy with either of these agents.
对常规化疗难治的晚期乳腺癌患者评估了氨茴霉素（AMSA）与派普卡霉素（peptichemio）联合治疗的效果。在33例可评估患者中，5例（15%）达到部分缓解，2例（6%）为未达部分缓解，9例（27%）疾病稳定，17例（52%）疾病进展。缓解的中位持续时间为6个月（范围：3 - 8个月）。疾病稳定的中位持续时间为5个月（范围：2 - 7个月）。骨髓抑制是剂量限制性毒性。与之前单独使用这两种药物之一进行单药治疗的经验相比，AMSA与派普卡霉素联合使用并未提高缓解率或缓解持续时间。
